Q-omics provides the consensus-scored HSF5 profile across patient tissues and cancer cell-line models. HSF5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, HSF5 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, HSF5 RNA expression shows 16,357 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, BLCA, and UVM as cancer lineages where HSF5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSF5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSF5 survival associations across molecular data types. HSF5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSF5 RNA expression–survival associations across cancer types. High HSF5 expression shows unfavorable associations in KIRP, but favorable associations in HNSC, SKCM, ESCA, LUAD and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for HSF5 RNA expression.
This table summarizes HSF5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for HSF5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSF5 shows lower tumor expression in BLCA, KICH, LUSC, COAD and THCA and higher tumor expression in KIRC. The BLCA box plot shows higher HSF5 RNA expression in normal versus tumor tissue (log2 FC = −0.092, t-test p < 0.001).
This table shows molecular features associated with HSF5 in patient tissues and cancer cell lines. In patient samples, HSF5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, HSF5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SKIN.
